Tags

Type your tag names separated by a space and hit enter

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
Res Sq. 2021 Jan 13RS

Abstract

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic N501 and Y501 SARS-CoV-2. Twenty human sera from the mRNA-based vaccine BNT162b2 trial exhibited equivalent neutralizing titers to the N501 and Y501 viruses.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Preprint

Language

eng

PubMed ID

33469576

Citation

Shi, Pei-Yong, et al. "Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera." Research Square, 2021.
Shi PY, Xie X, Zou J, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Res Sq. 2021.
Shi, P. Y., Xie, X., Zou, J., Fontes-Garfias, C., Xia, H., Swanson, K., Cutler, M., Cooper, D., Menachery, V., Weaver, S., & Dormitzer, P. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Research Square. https://doi.org/10.21203/rs.3.rs-143532/v1
Shi PY, et al. Neutralization of N501Y Mutant SARS-CoV-2 By BNT162b2 Vaccine-elicited Sera. Res Sq. 2021 Jan 13; PubMed PMID: 33469576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. AU - Shi,Pei-Yong, AU - Xie,Xuping, AU - Zou,Jing, AU - Fontes-Garfias,Camila, AU - Xia,Hongjie, AU - Swanson,Kena, AU - Cutler,Mark, AU - Cooper,David, AU - Menachery,Vineet, AU - Weaver,Scott, AU - Dormitzer,Philip, Y1 - 2021/01/13/ PY - 2021/1/20/entrez PY - 2021/1/21/pubmed PY - 2021/1/21/medline JF - Research square JO - Res Sq N2 - Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic N501 and Y501 SARS-CoV-2. Twenty human sera from the mRNA-based vaccine BNT162b2 trial exhibited equivalent neutralizing titers to the N501 and Y501 viruses. UR - https://www.unboundmedicine.com/medline/citation/33469576/Neutralization_of_N501Y_mutant_SARS_CoV_2_by_BNT162b2_vaccine_elicited_sera_ L2 - https://doi.org/10.21203/rs.3.rs-143532/v1 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.